Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

Director Shareholding

24 Feb 2005 07:04

Marchpole Holdings PLC24 February 2005 24 February 2005 Marchpole Holdings plc (the 'Company') Directors' interests Following approval by the Remuneration Committee, the executive Directors of theCompany have been granted the following share options ('Options') over newordinary shares of 1 pence each ('Ordinary Shares') under the Marchpole Holdingsplc 2002 Unapproved Share Option Scheme adopted by the Company at the AnnualGeneral Meeting held on 31 October 2002. All Options were granted on 21 February 2005, are exercisable at a price of25.75 pence per share and vest and become exercisable in three equal tranches onand from each twelfth month anniversary of the date of grant on the attainmentof a market capitalisation of the Company of £60 million, £70 million and £80million respectively. Director Number of Options over new Ordinary SharesGreg Tufnell, Chief Executive 900,000Justin Hampshire, Finance Director 900,000Michael Morris, Executive Director 900,000 The additional grant of 3,250,000 Options in the Company has been made toMichael Morris at a exercise price of 25.75 pence per share, such share optionsvesting and becoming exercisable in two equal tranches on each twelfth monthanniversary on the date of grant and on the achievement of a marketcapitalisation of the Company of £50 million and £55 million respectively. The Directors have the following interests in the Company: Director Number of Ordinary % of issued Shares share capital Christopher Phillips, Chairman 500,000 0.38Greg Tufnell, Chief Executive - -Justin Hampshire, Finance Director 500,000 0.38Michael Morris, Executive Director 25,521,715 19.21Raymond Harris, Non-Executive Director 30,000 0.02 The Michael Morris 1997 Trust 10,000,000 7.55 Enquiries: Justin Hampshire, Marchpole Holdings 020 7908 7777 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
11th Feb 20197:00 amRNSBoard Change
25th Jan 201911:10 amRNSPublication of F-4
18th Jan 20197:00 amRNSNew Deferred Bonus Plan
15th Jan 20197:00 amRNSBGS-649 Phase 2b data to be Presented at ENDO 2019
27th Dec 201810:02 amRNSDirector/PDMR Shareholding
24th Dec 20187:00 amRNSDirector/PDMR Shareholding
18th Dec 20187:00 amRNSPositive results from safety extension study
17th Dec 20186:25 pmRNSPositive results from safety extension study
17th Dec 20183:44 pmRNSAIM Rule 17 Disclosure Statement
10th Dec 20187:00 amRNSPresentation at BMO Healthcare Conference
5th Dec 20181:09 pmRNSProposed combination of Mereo and OncoMed
26th Nov 20187:00 amRNSIssue of Warrants
5th Nov 20187:00 amRNSFirst patient dosed in Phase 2 study
31st Oct 20183:37 pmRNSTotal Voting Rights
15th Oct 20187:00 amRNSCompletion of Patient Enrolment in Phase 2b study
1st Oct 201810:00 amRNSRevised Credit Facility and Issue of Warrants
3rd Sep 20187:00 amRNSBlock Listing Application
31st Aug 20186:25 pmRNSCorrection to Issued Share Capital
8th Aug 20187:00 amRNSMereo BioPharma Interim Results 2018
23rd Jul 20187:00 amRNSNotice of Interim Results
23rd Jul 20187:00 amRNSExercise of Options
21st Jun 201812:52 pmRNSResult of Annual General Meeting
29th May 20187:00 amRNSSuccessful Completion of PrimaryBid Offer
25th May 20184:31 pmRNSPrimaryBid.com Offer
22nd May 20187:00 amRNSNotice of AGM
27th Apr 20187:00 amRNSGrant of Options
26th Apr 20187:00 amRNSUpdate on Offering & Application to List on Nasdaq
9th Apr 201811:34 amRNSOffering and Application to List on Nasdaq
6th Apr 20181:03 pmRNSResult of General Meeting
3rd Apr 20187:00 amRNSPublication of Annual Report
26th Mar 20187:00 amRNSMereo BioPharma Files for Proposed Global Offering
23rd Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSPUBLICATION OF NOTICE OF GENERAL MEETING
20th Mar 20187:00 amRNSMereo selected for oral presentation at ATS 2018
19th Mar 20187:00 amRNSMereo: Positive Top-Line Results for BGS-649
26th Feb 20187:00 amRNSMereo BioPharma Appoints Wills Hughes-Wilson
2nd Jan 20187:00 amRNS£10m credit facility drawdown & issue of warrants
18th Dec 20177:00 amRNSMereo Plans to Conduct Registered IPO in the US
13th Dec 20177:00 amRNSMereo BioPharma: Business Update
11th Dec 20177:00 amRNSPositive results from Phase 2 trial with BCT-197
13th Nov 20177:00 amRNSBPS-804 receives PRIME designation
6th Nov 201712:19 pmRNSHolding(s) in Company
30th Oct 20177:00 amRNSMereo announces agreement with AstraZeneca
18th Sep 20177:00 amRNSMereo to Present at Cantor Healthcare Conference
5th Sep 20177:00 amRNSUpdate on BGS-649 Phase 2b Study
22nd Aug 20179:17 amRNSIssue of Warrants
8th Aug 20177:12 amRNSInterim Results
3rd Jul 20177:00 amRNSNotice of Results
27th Jun 201711:23 amRNSResult of AGM
15th May 20177:00 amRNSUpdate on acumapimod Phase 2 Study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.